What to Avoid When Taking Ajovy (Fremanezumab)
Medically reviewed by Lauren Okafor | MD, The Frank H Netter MD School of Medicine, Loyola University Medical Center on July 26th, 2026.
Published on July 27th, 2026. Updated on July 27th, 2026.
Key takeaways
Fremanezumab has few confirmed drug interactions, but combining it with other CGRP inhibitors or cardiovascular medications warrants a conversation with your doctor before proceeding.
Proper injection technique, including rotating sites and warming the syringe to room temperature, directly affects both safety and how well you tolerate each dose.
Pregnancy and a serious cardiovascular history are the two patient profiles that require the most careful evaluation before starting fremanezumab.
Lifestyle migraine triggers like alcohol, poor sleep, and dehydration should still be actively managed even while on a preventive biologic like Ajovy.
Hypersensitivity reactions, though uncommon, are the most urgent safety signal to recognize. Facial swelling, difficulty breathing, or a severe rash after injection requires immediate medical attention.
What Fremanezumab Is and Why Precautions Matter
Fremanezumab (brand name Ajovy) is a monoclonal antibody designed to prevent migraine by targeting calcitonin gene-related peptide (CGRP), a protein heavily involved in migraine pain signaling. It is approved for both episodic and chronic migraine prevention in adults and is given as a subcutaneous injection either monthly or once every three months.
Because CGRP does more than trigger migraines, it also helps regulate blood vessel tone and cardiovascular function, understanding what to avoid while on fremanezumab is genuinely important. A missed dose, an improper injection, or an unrecognized contraindication can reduce the drug's effectiveness or, in rarer cases, create safety concerns. The sections below walk through the most clinically relevant avoidances for anyone starting or already using Ajovy.
Drug Interactions to Be Aware Of
Fremanezumab has a favorable interaction profile compared to many traditional migraine preventives. No major formally documented drug-drug interactions appear in the prescribing information. That said, a few areas deserve attention.
Using fremanezumab alongside another CGRP-targeting agent, such as erenumab, galcanezumab, or eptinezumab, means two therapies are working on the same biological pathway simultaneously. The additive effects and safety profile of that combination have not been well studied, so it should be discussed with a neurologist rather than self-initiated.
Patients who regularly use triptans or ergotamine-based medications should flag this to their provider. These acute treatments also influence vascular and pain pathways, and while no confirmed harmful interaction has been established, combined use is still an area of ongoing clinical interest.
Finally, because CGRP has vasodilatory properties, patients on blood pressure medications may benefit from periodic monitoring after starting fremanezumab, particularly if they notice any unexpected changes in cardiovascular symptoms.
Conditions and Patient Profiles That Require Extra Caution
Certain patient profiles call for a more careful conversation before starting Ajovy.
A known hypersensitivity to fremanezumab or any of its inactive ingredients is a hard contraindication. Reactions can include rash, swelling, and difficulty breathing, and anyone with a history of severe allergic responses to biologics should discuss this explicitly with their prescriber.
Patients with serious cardiovascular disease, including a recent stroke or myocardial infarction, should approach fremanezumab with caution. CGRP plays a protective role in cardiovascular tissue, and while short-term clinical trials have not raised major alarms, longer-term real-world data in high-risk cardiac populations is still accumulating.
Pregnancy and breastfeeding represent another area of genuine uncertainty. Monoclonal antibodies can cross the placenta, especially in the second and third trimesters, and very little data exists on fetal safety. Anyone who is pregnant, planning to become pregnant, or currently nursing should have a thorough risk-benefit discussion with both their neurologist and their obstetric provider before continuing treatment.
Injection Site and Administration Mistakes to Avoid
Because fremanezumab is self-administered by injection, technique matters as much as the medication itself. Several common mistakes can reduce tolerability or compromise the drug's integrity.
Never inject into skin that is bruised, red, tender, scarred, or affected by a skin condition such as psoriasis or eczema. These areas absorb the medication unpredictably and increase the risk of local reactions. Rotating among the abdomen, upper thigh, and upper arm helps reduce site fatigue and irritation.
Do not shake the autoinjector or prefilled syringe at any point. Fremanezumab is a protein-based biologic, and agitation can damage its molecular structure, potentially reducing effectiveness or increasing the risk of an immune response.
A step many patients skip is allowing the syringe or autoinjector to sit at room temperature for 30 minutes before injecting. Injecting a cold solution directly from the refrigerator is one of the more common causes of injection-site pain and redness. This simple step significantly improves comfort.
Dosing Option |
Total Fremanezumab Dose |
Key Considerations |
|---|---|---|
Monthly injection |
225 mg per dose |
Easier to remember alongside other monthly routines; more frequent opportunity to catch missed doses early |
Quarterly injection |
675 mg per dose (3 injections on same day) |
Fewer administration days per year; a missed or delayed dose may mean a longer gap in CGRP suppression |
Both schedules |
Requires refrigeration until 30 min before use |
Injection site rotation and proper technique apply equally to both regimens |
Lifestyle Factors That May Undermine Treatment
Fremanezumab reduces the biological basis for migraine attacks, but it does not eliminate all triggers. Continuing to expose yourself to well-known migraine triggers while on Ajovy can make the treatment appear less effective than it actually is, and may result in premature discontinuation of a therapy that is otherwise working.
Alcohol is among the most widely recognized migraine triggers. While it does not directly interact with fremanezumab at a pharmacokinetic level, regular or heavy drinking can independently provoke migraine attacks and obscure your ability to judge whether the medication is reducing your frequency. Moderation or avoidance is a reasonable goal for most people on preventive therapy.
Inconsistent sleep schedules, chronic dehydration, and prolonged high-stress periods are similarly well-documented triggers. Preventive biologics work best when paired with consistent lifestyle habits. Think of fremanezumab as lowering your threshold for attacks, while trigger management keeps you from crossing it.
Dose schedule adherence is also a lifestyle factor worth emphasizing. Missing injections or self-adjusting the schedule reduces the drug's steady-state effect on CGRP. Setting a recurring calendar reminder or linking your injection day to another monthly habit can help maintain consistency.
Signs That Warrant Stopping and Contacting a Doctor
Most people tolerate fremanezumab well, but a few warning signs require prompt medical attention rather than a wait-and-see approach.
A serious hypersensitivity or allergic reaction is the most urgent possible concern. Swelling of the face, lips, or throat, difficulty breathing, or a severe rash appearing within hours of an injection should be treated as a medical emergency. This type of reaction is uncommon but has been reported with CGRP-targeting biologics.
Persistent or worsening constipation has been reported with anti-CGRP therapies as a class. CGRP is present in gut tissue, and blocking it may slow gastrointestinal motility in some individuals. If constipation becomes severe or does not resolve, contact your provider rather than managing it indefinitely on your own.
New or unusual cardiovascular symptoms, including chest pain, palpitations, or unexpected changes in blood pressure, should also prompt a call to your doctor. While fremanezumab is not known to cause these symptoms in most patients, its cardiovascular effects in people with pre-existing conditions are still an area of active monitoring.
Frequently Asked Questions
Alcohol does not have a direct pharmacokinetic interaction with fremanezumab, but it is a well-established migraine trigger. Regular drinking can make it harder to tell whether Ajovy is working effectively. Moderating or avoiding alcohol is generally advisable for anyone managing chronic or episodic migraines, regardless of their preventive medication.
No formally documented major interaction exists between fremanezumab and triptans, but the combination affects overlapping pain pathways. Some providers prefer to monitor patients using both regularly. Ergotamine derivatives also warrant discussion. Always share your full medication list with your prescribing clinician before starting or adjusting Ajovy.
Adequate safety data for fremanezumab during pregnancy or breastfeeding does not yet exist. Monoclonal antibodies can cross the placenta, particularly in later trimesters. If you are pregnant, planning a pregnancy, or nursing, discuss the potential risks and benefits carefully with your neurologist or OB before continuing or starting treatment.
If you miss a scheduled injection, administer it as soon as you remember and then resume your original dosing schedule from that new date. Do not double up doses. Consistency is important because fremanezumab relies on maintaining steady drug levels to suppress CGRP activity effectively. Contact your provider if you are unsure how to adjust your schedule.
There is no universally established washout period required when switching between CGRP inhibitors, but transitioning without medical guidance is not recommended. Overlapping two agents that target the same pathway may increase side effect risk. Your neurologist can help you plan a safe transition timeline based on your current medication and migraine history.
The Bottom Line
Fremanezumab (Ajovy) is generally well tolerated for migraine prevention, but getting the most out of treatment means paying close attention to injection technique, recognizing key contraindications, and keeping your dose schedule consistent. Lifestyle triggers like alcohol and poor sleep still need active management even on a preventive biologic. Patients with cardiovascular concerns or who are pregnant need especially careful medical review before starting. Doctronic has conducted over 22 million AI consultations, and its platform can help you review your full medication list and migraine plan with 99.2% treatment plan alignment with board-certified physicians, available 24/7 for free. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.
Related articles
Get pain relief advice
Chat Now